Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) announced the granting of equity incentives to seven new non-executive employees under its 2025 Inducement Equity Plan. The grants include 54,360 restricted stock units (RSUs) and options to purchase 38,850 shares at an exercise price of $5.47 per share.

The options will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over three years. The RSUs will vest 25% after one year, followed by quarterly vesting of 6.25% on specified dates. All grants are subject to continued employment and were approved as material inducements under Nasdaq Listing Rule 5635(c)(4).

News Market Reaction

-1.12%

1 alert

-1.12% News Effect

-$2M Valuation Impact

$215M Market Cap

0.0x Rel. Volume

On the day this news was published, TRDA declined 1.12%, reflecting a mild negative market reaction. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $215M at that time.

Data tracked by StockTitan Argus on the day of publication.

BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 54,360 restricted stock units (“RSUs”) and options to purchase 38,850 shares of the Company’s common stock to seven newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of September 1, 2025. The options have an exercise price of $5.47 per share, which is equal to the closing price of the Company's common stock on August 29, 2025. The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

One-fourth of the shares underlying each employee’s option will vest on the one-year anniversary of the vesting commencement date and thereafter the remaining 75% will vest in thirty-six equal monthly installments, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the vesting commencement date, in each case, subject to each employee’s continued employment with the Company through each vesting date. One-fourth of the RSUs will vest on the one-year anniversary of the vesting commencement date, and 6.25% shall vest quarterly thereafter on each subsequent vesting date, with such vesting dates of March 1, June 1, September 1 and December 1 of each subsequent year, in each case, subject to each employee’s continuous service with the Company through each vesting date. The options and RSUs are subject to the terms and conditions of the Inducement Plan approved by the Company’s Board of Directors in March 2025 and the terms and conditions of award agreements covering the grants.

About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.

Investor Contact
Karla MacDonald
Chief Corporate Affairs Officer
kmacdonald@entradatx.com

FAQ

What equity incentives did Entrada Therapeutics (TRDA) grant to new employees in September 2025?

Entrada granted 54,360 RSUs and options to purchase 38,850 shares at $5.47 per share to seven new non-executive employees under its 2025 Inducement Equity Plan.

What is the vesting schedule for TRDA's September 2025 employee stock options?

The options vest over 4 years, with 25% vesting after one year and the remaining 75% vesting in 36 monthly installments.

How do the RSUs vest in Entrada Therapeutics' September 2025 inducement grants?

The RSUs vest 25% after one year, followed by 6.25% quarterly vesting on March 1, June 1, September 1, and December 1 of subsequent years.

What was the exercise price for TRDA's September 2025 inducement stock options?

The exercise price was set at $5.47 per share, equal to the closing price of Entrada's common stock on August 29, 2025.